Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Celldex Therapeutics Inc patents


Recent patent applications related to Celldex Therapeutics Inc. Celldex Therapeutics Inc is listed as an Agent/Assignee. Note: Celldex Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with Celldex Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Celldex Therapeutics Inc-related inventors


Biomarkers related to treatment of cancer with her3 and egfr inhibitors

Provided herein are methods of treating cancers expressing specific biomarkers with her3 and/or egfr inhibitors, and provided herein are also biomarkers and uses thereof in determining likelihood of effective cancer treatment with her3 and/or egfr inhibitors. In one aspect, the disclosure provides methods for treating a cancer, comprising administering to a patient diagnosed with said cancer a therapeutically effective amount of a her3 inhibitor, an egfr inhibitor, or a combination of a her3 inhibitor and an egfr inhibitor. ... Celldex Therapeutics Inc

Agonistic antibodies that bind human cd40 and uses thereof

Isolated monoclonal agonistic antibodies which bind to human cd40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.. ... Celldex Therapeutics Inc

Anti-met antibodies and methods of use thereof

Provided herein are compositions, methods and uses involving antibodies that specifically bind to met, a receptor tyrosine kinase, and modulate the expression and/or activity of met. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. ... Celldex Therapeutics Inc

Cd27 agonists

The invention provides cd27 agonists comprising a first component that is an anti-cd27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an fc receptor and the cd27 agonist stimulates t cell activity without the need for fc receptor interaction. ... Celldex Therapeutics Inc

Compositions using antibodies directed to gpnmb and uses thereof

The present invention relates to antibodies, including fully human monoclonal antibodies, with specificity to gpnmb, and uses of such antibodies. The present invention further provides compositions that increase expression of gpnmb on the surface of tumor cells, and methods of using such compositions to increase the anti-cancer activity or other therapeutic efficacy of the antibodies and immunoconjugates provided herein.. ... Celldex Therapeutics Inc

Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment

This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-pd-1 antibody and an anti-cd27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.. ... Celldex Therapeutics Inc

Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen

The invention described herein is related to antibodies directed to the antigen tim-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen tim-1. ... Celldex Therapeutics Inc

Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment

This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-pd-1 antibody and an anti-cd27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.. ... Celldex Therapeutics Inc

Anti-kit antibodies and uses thereof

Provided herein, in one aspect, are antibodies that immunospecifically bind to a human kit antigen comprising the fourth and/or fifth extracellular ig-like domains (that is, d4 and/or d5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit kit activity, such as ligand-induced receptor phosphorylation. ... Celldex Therapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Celldex Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Celldex Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###